Is Jade Biosciences, Inc. Common Stock profitable?

Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.

What is Jade Biosciences, Inc. Common Stock's earnings per share?

Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.

Where does Jade Biosciences, Inc. Common Stock's income statement data come from?

Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Jade Biosciences, Inc. Common Stock JBIO Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Research and development	$93.12M+43.3%	$64.97M+1.2%	$64.22M+66.3%	$38.62M+158%
General and administrative	$20.42M+90.2%	$10.74M-37.5%	$17.19M+17.6%	$14.62M+81.9%
Other operating expenses	$113.54M+50.0%	$75.71M-7.0%	$81.41M+52.9%	$53.24M+131%
Total operating expenses	$113.54M+50.0%	$75.71M-7.0%	$81.41M+52.9%	$53.24M+131%
Operating income	-$113.54M-50.0%	-$75.71M+7.0%	-$81.41M-52.9%	-$53.24M-131%
Other income (expense), net	——	-$11.32M-290%	$5.94M+239%	$1.75M+2,726%
Income before income taxes	——	——	-$75.47M—	——
Income tax expense	$58K—	——	$56K+124%	$25K+733%
Net income	-$127.41M-46.4%	-$87.03M-15.2%	-$75.52M-46.6%	-$51.51M-124%
Diluted earnings per share	-$13.55+35.7%	-$21.07-632%	-$2.88-36.5%	-$2.11—
Basic earnings per share	-$13.55+35.7%	-$21.07-632%	-$2.88-36.5%	-$2.11+94.1%
Weighted-average shares, diluted	102.5M+175%	37.3M-64.1%	103.9M+6.3%	97.7M—
Weighted-average shares, basic	102.5M+175%	37.3M-64.1%	103.9M+6.3%	97.7M+167%
Change In Fair Value Of Convertible Notes Payable	$21.58M—	——	——	——
Interest Income (Expense), Nonoperating	$7.78M+161%	$2.98M-49.8%	$5.95M+225%	$1.83M+2,717%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$127.28M-45.8%	-$87.3M-16.7%	-$74.84M-44.2%	-$51.92M-126%
Net unrealized losses	——	-$13K-102%	$681K—	——
Foreign currency translation gains (losses)	-$28K—	——	——	——
Other income, net (Note 6)	——	$1.39M+138,800%	-$1K-100%	$1.86M+2,225%
EBIT	-$113.54M-50.0%	-$75.71M+7.0%	-$81.41M-52.9%	-$53.24M-131%
EBITDA	-$113.52M-50.5%	-$75.43M+7.2%	-$81.31M-52.9%	-$53.17M-131%
EBITDA	-$113.52M-50.5%	-$75.43M+7.2%	-$81.31M-52.9%	-$53.17M-131%
EBIT	-$113.54M-50.0%	-$75.71M+7.0%	-$81.41M-52.9%	-$53.24M-131%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Jade Biosciences, Inc. Common Stock profitable?: Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.
What is Jade Biosciences, Inc. Common Stock's earnings per share?: Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.
Where does Jade Biosciences, Inc. Common Stock's income statement data come from?: Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.